Evidence map›Paper›PMID 41838850›Full record

ArticleClinical neuropharmacology

Antisuicidal Effect of Lamotrigine Augmentation in Treatment-Resistant Depression: A Case Report.

Kimberly Hsiung, Terako Amison

Abstract readCase Reports
In one paragraph

Article in Clinical neuropharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kimberly HsiungDepartment of Psychiatry and Behavioral Sciences.ORCID 0000-0001-5568-2019
Terako AmisonWork/Life Connections, Vanderbilt University Medical Center, Nashville, TN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTreatment-resistant depression (TRD) is a serious public health burden in the United States and comes with an extremely high suicide risk relative to the general population. Lamotrigine, though approved for use only in bipolar disorder, has been found to augment the effects of an antidepressant in treatment-resistant individuals. However, studies showing an antisuicidal effect of lamotrigine in the TRD population are limited. The objective of this paper is to describe a case of a 58-year-old male with TRD and chronic suicidality who was treated with lamotrigine augmentation of the serotonin-norepinephrine reuptake inhibitor, duloxetine, and experienced a sustained clinical improvement of his suicidality.

methodsClinical changes in depression and suicidality after initiation of lamotrigine are presented.

resultsThe patient experienced a brief improvement in depression and sustained improvement in suicidality for 2 years.

conclusionsWhile there remains insufficient evidence in the literature for a clinical recommendation of the use of lamotrigine for suicidality in the TRD population, our case report introduces the novel possibility of an antisuicidal effect of lamotrigine at the individual level. We suggest clinicians consider its use when other, more robust treatments for suicidality have failed.

Indexed as

Antidepressive AgentsDepressive Disorder, Treatment-ResistantDuloxetine HydrochlorideLamotrigineDrug Therapy, CombinationHumansMaleMiddle AgedSerotonin and Noradrenaline Reuptake InhibitorsAntidepressive AgentsDuloxetine HydrochlorideLamotrigineSerotonin and Noradrenaline Reuptake Inhibitorsantidepressive agentscase reportduloxetinelamotriginesuicidal ideationtreatment-resistant depressive disorder

Identifiers

PMID41838850
PMCPMC12975012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.